LNTH-2403 (LRRC15 Targeted Antibody)

May 19, 2026 — Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, 2026; Chicago, IL).

The company highlighted two ASCO items: (1) a poster in the Sarcoma session (Poster 376b; June 1) describing a Phase 1/2, multi-center, open-label study of LNTH-2403, an LRRC15-targeted lutetium-177–labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma. The study evaluates safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity; the presenter is Noah Federman (UCLA). (2) A “Publication Only” abstract (e17126) on real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer, first-authored by Emma Billmyer (The Analysis Group).

Business/clinical significance: the announcement signals continued clinical development of Lantheus’ targeted radiopharmaceutical candidate LNTH-2403 and dissemination of real-world evidence supporting use patterns for piflufolastat F 18 imaging in prostate cancer.